Pediatric COVID-19 Vaccine Dosing Quick Reference Guide

Moderna, Pfizer-BioNTech, and Novavax COVID-19 Vaccine Products

**Moderna COVID-19 Vaccine Products**

*2023–2024 Formula*

- Dark blue cap/ green label
- 25 mcg/0.25 ml single-dose vial
- 50 mcg/0.5 ml single-dose vial

- Also available in a 0.5 ml single dose prefilled syringe

**Pfizer-BioNTech COVID-19 Vaccine Products**

*2023–2024 Formula*

- Yellow cap
- Blue cap
- Gray cap
- Also available in a 0.3 ml single dose prefilled syringe

**Novavax COVID-19 Vaccine Product**

*2023–2024 Formula*

- Dark blue cap/ blue label
- 5 mcg/0.5 ml

---

**Unvaccinated**

- **Previously received vaccine(s)**

  - **Recommended 2023–2024 vaccine**

    - Moderna dark blue cap/green label OR Pfizer yellow cap
      - Dose 1
      - Dose 2
      - 4–8 weeks after dose 1
      - Dose 2
      - 3–8 weeks after dose 1
      - Dose 3
      - ≥8 weeks after dose 2

- **Previously Vaccinated with Original or Bivalent**

  - 1 dose any Moderna
  - 2 or more doses any Moderna
  - 1 dose any Pfizer
  - 2 doses any Pfizer
  - 3 or more doses any Pfizer

---

**6 months – 4 years**

- **Previously received vaccine(s)**

  - **Recommended 2023–2024 vaccine**

    - Moderna dark blue cap/green label OR Pfizer yellow cap
      - Dose 1
      - Dose 2
      - 4–8 weeks after dose 1
      - Dose 2
      - 3–8 weeks after dose 1
      - 1 dose
      - ≥8 weeks after dose 1
      - Dose 3
      - ≥8 weeks after dose 2

---

**5a – 11 years**

- **Previously received vaccine(s)**

  - **Recommended 2023–2024 vaccine**

    - Moderna dark blue cap/green label OR Pfizer blue cap
      - 1 dose
      - 1 dose

---

**12 years and older**

- **Previously received vaccine(s)**

  - **Recommended 2023–2024 vaccine**

    - Moderna dark blue cap/blue label OR Pfizer gray cap OR Novavax dark blue cap/blue label
      - 1 dose
      - 1 dose
      - Dose 1
      - 3–8 weeks after dose 1

- **Previously Vaccinated with Original or Bivalent**

  - 1 or more doses any mRNA vaccine
  - 1 or more doses Novavax or Janssen, including in combination with any mRNA vaccine dose(s)

---

*a. For children who turn 4 to 5 years during their vaccine series, follow dosing recommendations based on age at the time of vaccination. For Pfizer vaccine, if the 10 mcg dose is the second dose, administer 3–8 weeks after the first dose; if it is the third dose, administer at least 8 weeks after the second dose.

b. COVID-19 vaccine doses from the same manufacturer should be administered whenever recommended. In the following circumstances, an age-appropriate COVID-19 vaccine from a different manufacturer may be administered: (1) Same vaccine not available at the vaccination site at the time of the clinic visit, (2) Previous dose unknown, (3) Person would otherwise not receive a recommended vaccine dose. (4) Person starts but unable to complete a vaccination series with the same COVID-19 vaccine due to a contraindication. A Vaccine Adverse Event Reporting System (VAERS) report is not indicated in these circumstances.

View online at [aap.org/CovidVaccineGuide](http://aap.org/CovidVaccineGuide)

Last updated November 2023
Pediatric COVID-19 Vaccine Dosing Quick Reference Guide

Moderna, Pfizer-BioNTech, and Novavax COVID-19 Vaccine Products for Individuals who are Moderately to Severely Immunocompromised

Moderna COVID-19 Vaccine Products

2023–2024 Formula

<table>
<thead>
<tr>
<th>Dark blue cap/ green label</th>
<th>Also available in a 0.5 ml single dose prefilled syringe</th>
</tr>
</thead>
<tbody>
<tr>
<td>25 mcg/0.25 ml 50 mcg/0.5 ml single-dose vial</td>
<td></td>
</tr>
</tbody>
</table>

Pfizer-BioNTech COVID-19 Vaccine Products

2023–2024 Formula

<table>
<thead>
<tr>
<th>Yellow cap</th>
<th>Blue cap</th>
<th>Gray cap</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 mcg/0.3 ml (dilute before use) 10 mcg/0.3 ml 30 mcg/0.3 ml single-dose vial</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Novavax COVID-19 Vaccine Product

2023–2024 Formula

<table>
<thead>
<tr>
<th>Dark blue cap/ blue label</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 mcg/0.5 ml</td>
</tr>
</tbody>
</table>

*Discard vial and excess volume after extracting a single dose.

Unvaccinated:

Previously received vaccine(s)

Recommended 2023–2024 vaccine

<table>
<thead>
<tr>
<th>Moderna dark blue cap/green label</th>
<th>OR</th>
<th>Pfizer yellow cap</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose 1</td>
<td>Dose 1</td>
<td></td>
</tr>
<tr>
<td>4 weeks after dose 1</td>
<td>3 weeks after dose 1</td>
<td></td>
</tr>
<tr>
<td>Dose 2</td>
<td>Dose 2</td>
<td></td>
</tr>
<tr>
<td>4 weeks after dose 1</td>
<td>3 weeks after dose 1</td>
<td></td>
</tr>
<tr>
<td>Dose 3</td>
<td>Dose 3</td>
<td></td>
</tr>
<tr>
<td>≥8 weeks after dose 2</td>
<td>≥8 weeks after dose 2</td>
<td></td>
</tr>
</tbody>
</table>

Previously Vaccinated with Original or Bivalent

<table>
<thead>
<tr>
<th>Moderna yellow cap</th>
<th>Blue cap</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose 1</td>
<td>Dose 1</td>
</tr>
<tr>
<td>4 weeks after dose 1</td>
<td>3 weeks after dose 1</td>
</tr>
<tr>
<td>Dose 2</td>
<td>Dose 2</td>
</tr>
<tr>
<td>3 weeks after dose 1</td>
<td>3 weeks after dose 1</td>
</tr>
<tr>
<td>Dose 3</td>
<td>Dose 3</td>
</tr>
<tr>
<td>≥8 weeks after dose 2</td>
<td>≥8 weeks after dose 2</td>
</tr>
</tbody>
</table>

Unvaccinated:

Previously received vaccine(s)

Recommended 2023–2024 vaccine

<table>
<thead>
<tr>
<th>Moderna dark blue cap/green label</th>
<th>OR</th>
<th>Pfizer blue cap</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose 1</td>
<td>Dose 1</td>
<td></td>
</tr>
<tr>
<td>4 weeks after dose 1</td>
<td>3 weeks after dose 1</td>
<td></td>
</tr>
<tr>
<td>Dose 2</td>
<td>Dose 2</td>
<td></td>
</tr>
<tr>
<td>4 weeks after dose 1</td>
<td>3 weeks after dose 1</td>
<td></td>
</tr>
<tr>
<td>Dose 3</td>
<td>Dose 3</td>
<td></td>
</tr>
<tr>
<td>≥8 weeks after dose 2</td>
<td>≥8 weeks after dose 2</td>
<td></td>
</tr>
</tbody>
</table>

Previously Vaccinated with Original or Bivalent

<table>
<thead>
<tr>
<th>Moderna dark blue cap/green label</th>
<th>OR</th>
<th>Pfizer blue cap</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose 1</td>
<td>Dose 1</td>
<td></td>
</tr>
<tr>
<td>4 weeks after dose 1</td>
<td>3 weeks after dose 1</td>
<td></td>
</tr>
<tr>
<td>Dose 2</td>
<td>Dose 2</td>
<td></td>
</tr>
<tr>
<td>4 weeks after dose 1</td>
<td>3 weeks after dose 1</td>
<td></td>
</tr>
<tr>
<td>Dose 3</td>
<td>Dose 3</td>
<td></td>
</tr>
<tr>
<td>≥8 weeks after dose 2</td>
<td>≥8 weeks after dose 2</td>
<td></td>
</tr>
</tbody>
</table>

12 years and older

Previously received vaccine(s)

Recommended 2023–2024 vaccine

<table>
<thead>
<tr>
<th>Moderna dark blue cap/gray label</th>
<th>OR</th>
<th>Novavax dark blue cap/blue label</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose 1</td>
<td>Dose 1</td>
<td></td>
</tr>
<tr>
<td>4 weeks after dose 1</td>
<td>3 weeks after dose 1</td>
<td></td>
</tr>
<tr>
<td>Dose 2</td>
<td>Dose 2</td>
<td></td>
</tr>
<tr>
<td>4 weeks after dose 1</td>
<td>3 weeks after dose 1</td>
<td></td>
</tr>
<tr>
<td>Dose 3</td>
<td>Dose 3</td>
<td></td>
</tr>
<tr>
<td>≥8 weeks after dose 2</td>
<td>≥8 weeks after dose 2</td>
<td></td>
</tr>
</tbody>
</table>

Previously Vaccinated with Original or Bivalent

<table>
<thead>
<tr>
<th>Moderna dark blue cap/blue label</th>
<th>OR</th>
<th>Novavax gray cap</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose 1</td>
<td>Dose 1</td>
<td></td>
</tr>
<tr>
<td>4 weeks after dose 1</td>
<td>3 weeks after dose 1</td>
<td></td>
</tr>
<tr>
<td>Dose 2</td>
<td>Dose 2</td>
<td></td>
</tr>
<tr>
<td>4 weeks after dose 1</td>
<td>3 weeks after dose 1</td>
<td></td>
</tr>
<tr>
<td>Dose 3</td>
<td>Dose 3</td>
<td></td>
</tr>
<tr>
<td>≥8 weeks after dose 2</td>
<td>≥8 weeks after dose 2</td>
<td></td>
</tr>
</tbody>
</table>

a. For children who turn 4 to 5 years during their vaccine series, follow dosing recommendations based on age at the time of vaccination.
b. COVID-19 vaccine doses from the same manufacturer should be administered whenever recommended. In the following circumstances, an age-appropriate COVID-19 vaccine from a different manufacturer may be administered: (1) Same vaccine not available at the vaccination site at the time of the clinic visit; (2) Previous dose unknown; (3) Person would otherwise not receive a recommended vaccine dose; (4) Person starts but unable to complete a vaccination series with the same COVID-19 vaccine due to a contraindication. A Vaccine Adverse Event Reporting System (VAERS) report is not indicated in these circumstances.
c. Individuals who are moderately to severely immunocompromised have the option to receive one additional dose of updated mRNA vaccine at least 8 weeks following the last recommended dose. Further additional doses may be administered at ≥8 week intervals, informed by clinical judgement of the healthcare provider and personal preference and circumstances.
d. For children who turn 11 to 12 years during their vaccine series, follow dosing recommendations based on age at the time of vaccination.

View online at aap.org/CovidVaccineGuide | Last updated November 2023
Previously Vaccinated with Original or Bivalent

**6 months – 4 years**

- Previously Unvaccinated
  - 1 dose any mRNA vaccine
- Previously Vaccinated with Original or Bivalent
  - 1 dose any mRNA vaccine
  - 2 or more doses any mRNA vaccine

**5 – 11 years**

- Previously Unvaccinated
  - 1 dose any mRNA vaccine
- Previously Vaccinated with Original or Bivalent
  - 1 dose any mRNA vaccine
  - 2 or more doses any mRNA vaccine

**12 years and older**

- Previously Unvaccinated
  - 1 dose any mRNA vaccine
- Previously Vaccinated with Original or Bivalent
  - 1 dose any mRNA vaccine
  - 2 or more doses any mRNA vaccine

---

**Moderately to Severely Immunocompromised Individuals**

**6 months – 4 years**

- Previously Unvaccinated
  - 1 dose any mRNA vaccine
- Previously Vaccinated with Original or Bivalent
  - 1 dose any mRNA vaccine
  - 2 or more doses any mRNA vaccine

**5 – 11 years**

- Previously Unvaccinated
  - 1 dose any mRNA vaccine
- Previously Vaccinated with Original or Bivalent
  - 1 dose any mRNA vaccine
  - 2 or more doses any mRNA vaccine

**12 years and older**

- Previously Unvaccinated
  - 1 dose any mRNA vaccine
- Previously Vaccinated with Original or Bivalent
  - 1 dose any mRNA vaccine
  - 2 or more doses any mRNA vaccine

---

For children who turn 4 to 5 years during their vaccine series, follow dosing recommendations based on age at the time of vaccination.

- **Previously Vaccinated with Original or Bivalent**
  - 1 dose any mRNA vaccine
  - 2 or more doses any mRNA vaccine

For children who turn 5 to 11 years during their vaccine series, follow dosing recommendations based on age at the time of vaccination.

- **Previously Vaccinated with Original or Bivalent**
  - 1 dose any mRNA vaccine
  - 2 or more doses any mRNA vaccine

For children who turn 12 years and older during their vaccine series, follow dosing recommendations based on age at the time of vaccination.

- **Previously Vaccinated with Original or Bivalent**
  - 1 dose any mRNA vaccine
  - 2 or more doses any mRNA vaccine

---

a. For children who turn 4 to 5 years during their vaccine series, follow dosing recommendations based on age at the time of vaccination.

b. COVID-19 vaccine doses from the same manufacturer should be administered whenever recommended. In the following circumstances, an age-appropriate COVID-19 vaccine from a different manufacturer may be administered: (1) Same vaccine not available at the vaccination site at the time of the clinic visit, (2) Previous dose unknown, (3) Person would otherwise not receive a recommended vaccine dose, (4) Person starts but unable to complete a vaccination series with the same COVID-19 vaccine due to a contraindication. A Vaccine Adverse Event Reporting System (VAERS) report is not indicated in these circumstances. 

c. Individuals who are moderately to severely immunocompromised have the option to receive one additional dose of updated mRNA vaccine at least 8 weeks following the last recommended dose. Further additional doses may be administered at ≥8 week intervals, informed by clinical judgement of the healthcare provider and personal preference and circumstances.

d. For children who turn 11 to 12 years during their vaccine series, follow dosing recommendations based on age at the time of vaccination.

View online at [aap.org/CovidVaccineGuide](https://aap.org/CovidVaccineGuide)

3 mcg/0.3 ml (dilute before use) three-dose vial
10 mcg/0.3 ml single-dose vial
30 mcg/0.3 ml single-dose vial

Also available in a 0.3 ml single dose prefilled syringe

a. For children who turn 4 to 5 years during their vaccine series, follow dosing recommendations based on age at the time of vaccination. For Pfizer vaccine, if the 10 mcg dose is the second dose, administer 3–8 weeks after the first dose; if it is the third dose, administer at least 8 weeks after the second dose.

b. COVID-19 vaccine doses from the same manufacturer should be administered whenever recommended. In the following circumstances, an age-appropriate COVID-19 vaccine from a different manufacturer may be administered: (1) Same vaccine not available at the vaccination site at the time of the clinic visit; (2) Previous dose unknown; (3) Person would otherwise not receive a recommended vaccine dose; (4) Person starts but unable to complete a vaccination series with the same COVID-19 vaccine due to a contraindication. A Vaccine Adverse Event Reporting System (VAERS) report is not indicated in these circumstances.

c. Individuals who are moderately to severely immunocompromised have the option to receive one additional dose of updated mRNA vaccine at least 8 weeks following the last recommended dose. Further additional doses may be administered at ≥8 week intervals, informed by clinical judgement of the healthcare provider and personal preference and circumstances.

d. For children who turn 11 to 12 years during their vaccine series, follow dosing recommendations based on age at the time of vaccination.

View online at aap.org/CovidVaccineGuide

Last updated November 2023
Novavax COVID-19 Vaccine Product
2023–2024 Formula

Dark blue cap/blue label

5 mcg/0.5 ml

12 years and older

Previously Vaccinated with Original or Bivalent

1 or more doses of Novavax

∅8 weeks after last dose

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3–8 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Previously Vaccinated with Original or Bivalent

1 or more doses of Novavax

∅8 weeks after last dose

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Moderately to Severely Immunocompromised Individuals

Novavax COVID-19 Vaccine Product
2023–2024 Formula

Dark blue cap/blue label

5 mcg/0.5 ml

Previously Vaccinated with Original or Bivalent

1 or more doses of Novavax

∅8 weeks after last dose

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Previously Vaccinated with Original or Bivalent

1 or more doses of Novavax

∅8 weeks after last dose

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3–8 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3–8 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3–8 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3–8 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3–8 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3–8 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3–8 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3–8 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3–8 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3–8 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3–8 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3–8 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3–8 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3–8 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3–8 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3–8 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3–8 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3–8 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3–8 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3–8 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3–8 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3–8 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3–8 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novavax dark blue cap/blue label

Dose 1
Dose 2
3–8 weeks after dose 1

Previously received vaccine(s)

Recommended vaccine

Unvaccinated

Novax...